Domerid

Quick links to important sections

Domerid

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domerid

Property Description
Active Ingredient Domperidone
Pharmacological Class Dopamine Antagonist, Prokinetic Agent
Primary Forms Tablet, Oral Suspension, Suppository
Common Use Relieving Nausea and Vomiting Symptoms
Origin Synthetic Compound (Benzimidazole Derivative)

Domerid: Definition, Active Ingredient, and Origin

Domerid is a medicinal product containing the single active substance Domperidone. It is classified as a single product and its active ingredient is a synthetic compound, chemically recognized as a derivative of the Benzimidazole class. This manufactured origin confirms its status as a pharmaceutical entity. The medicine's composition utilizes pharmaceutical excipients that act as a vehicle to deliver the core ingredient, a peripheral dopamine D2-receptor blocker. Domperidone is classified based on its pharmacological properties, as the medicine targets digestive receptors effectively without significant central nervous system effects.


Pharmacological Classification and Available Forms

Domerid belongs to the established pharmacological class of dopamine antagonists and is functionally categorized as both a prokinetic agent and an anti-emetic agent. Its primary distinction lies in the prokinetic agent role, which is clinically recognized for actively stimulating and normalizing gastrointestinal peristalsis. The anti-emetic categorization refers to its ability to help relieve symptoms of nausea and vomiting. The drug is prepared in various high-level dosage forms, including the most common oral tablet and oral suspension, and as a suppository for rectal administration.


General Therapeutic Purpose of the Prokinetic Agent

The general purpose of Domerid is to restore proper movement in the digestive system, helping to manage symptoms that arise from sluggish or disordered motility. By enhancing the rate of gastric emptying and increasing the tone of the valve between the esophagus and stomach, the medicine effectively counters the feeling of discomfort or fullness. This targeted action provides the core benefit of reducing the sensations of nausea and the occurrence of vomiting associated with delayed stomach transit.

Regulatory References

  1. NIH - MedlinePlus on Domperidone

What side effects are possible with Domerid?

Possible Side Effects and Safety Information

Domerid's (Domperidone) official safety profile is organized by regulatory documents based on frequency and the body system affected. The most serious regulatory concern involves the Cardiac System.

The drug is associated with a rare but serious risk of ventricular arrhythmia, QT interval prolongation, and sudden cardiac death. This risk is officially noted to be increased with daily doses greater than 30 mg and with long-term use.


Adverse Reactions by Frequency

Frequency Category Examples of Listed Effects
Common Dry mouth, headache, diarrhea
Uncommon Anxiety, somnolence (drowsiness), rash, galactorrhea, breast pain/tenderness
Rare Gynecomastia, amenorrhea (menstrual irregularities)
Very Rare Extrapyramidal disorder (uncontrolled movements), severe hypersensitivity reactions, urinary retention

Safety Restrictions and Considerations

The medicine is subject to several official safety restrictions. It is contraindicated in patients who have pre-existing conditions that affect heart rhythm, such as a prolonged QTc interval, or significant electrolyte disturbances. Its use is also prohibited in individuals with moderate or severe hepatic (liver) impairment, and in those co-administering certain medications, such as QT-prolonging drugs or potent CYP3A4 inhibitors.

Population-Specific Notes: Regulatory information notes that the risk of serious ventricular arrhythmias is higher in older adults and that extrapyramidal symptoms are more likely in the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that an overdose of Domerid (Domperidone) carries a significant risk of serious manifestations and mandates immediate medical attention. The officially documented signs of overdose primarily involve the Central Nervous System (CNS) and cardiovascular system.


Documented Overdose Presentations

Classification Manifestation Required Action
CNS Effects Drowsiness, disorientation, difficulty in speaking, extrapyramidal symptoms, seizure. Seek immediate medical attention.
Cardiac Risks QTc interval prolongation, irregular heartbeat, fainting, risk of serious ventricular arrhythmias. Get emergency help immediately.

Official Emergency and Management Requirements

All suspected overdose cases require immediate medical attention. The prescribing information emphasizes that management should consist of standard symptomatic treatment and supportive care, as no specific antidote is known. Due to the documented risk of QTc interval prolongation, ECG monitoring should be undertaken during treatment for overdose. Specific populations, such as children, are noted as being more susceptible to neurological effects, including extrapyramidal symptoms, following excessive exposure. Furthermore, the risk of serious cardiac outcomes is specifically noted in patients over 60 years of age or those taking daily doses above 30 mg, factors which may be exacerbated in an overdose scenario.

Therapeutic Uses of Domerid

Quick Facts: Uses of Domerid

  • Relief of Nausea and Vomiting: Used for the short-term management of symptoms of nausea and vomiting.
  • Symptom Management in Gastrointestinal Disorders: May be used to help manage symptoms associated with certain upper gastrointestinal motility disorders.

What Domerid Treats: Main Uses and Benefits

Domerid (Domperidone) is a compound utilized for the symptomatic relief of nausea and vomiting across various underlying causes. It may be considered for short-term use in adults and adolescents to address these symptoms.

Additionally, Domerid is employed in the management of specific gastrointestinal motility disorders. Its use may support the movement of contents through the stomach, which can help to alleviate symptoms associated with conditions such as gastroparesis (delayed stomach emptying). This therapeutic support is generally reserved for patients who have not responded to standard treatment options. The compound is utilized in certain countries under specific investigational programs for patients with severe, refractory gastrointestinal conditions.

In certain regions, Domerid is specifically recommended for the relief of symptoms of nausea and vomiting.

It is important that patients consult with a healthcare professional to determine if Domerid is appropriate for their specific condition.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Domerid

The official eligibility profile for Domperidone is defined by strict regulatory criteria, primarily due to the associated risk of cardiac adverse events.

Eligibility Scope
Populations for whom use is allowed: Adults and adolescents ge 12 years of age and weighing ge 35 kg for the short-term relief of nausea and vomiting symptoms (EU/UK-licensed use).
Populations for whom use is not recommended: Children lt 12 years or lt 35 kg; breastfeeding women; older adults (specifically gt 60 years) due to increased cardiac risk.

Populations for whom use is contraindicated (Must Not Use):

  • Patients with moderate or severe hepatic impairment (liver disease).
  • Patients with underlying cardiac diseases (e.g., congestive heart failure) or known existing QTc prolongation.
  • Patients with significant electrolyte disturbances or a prolactin-releasing pituitary tumour.
  • Patients concurrently using QT-prolonging drugs or potent CYP3A4 inhibitors.

Condition-Specific Eligibility Rules:

  • Severe Renal Impairment requires a reduction of dosing frequency.
  • Use during Pregnancy is only permitted when justified by the anticipated therapeutic benefit.
  • In the US, general use is not FDA-approved and is limited to patients ge 12 years of age with severe gastrointestinal conditions via an Expanded Access Investigational New Drug (IND) protocol.

Connection to the overall eligibility profile: Official regulatory documents strictly define who can and cannot use the medicine by prohibiting use in populations with compromised organ function, known cardiac issues, and those concurrently taking specific medications, while further restricting use by age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific, severe restrictions for the use of Domerid (Domperidone) due to documented interaction patterns. These constraints relate primarily to cardiac risk modification and drug metabolism.

Contraindicated Combinations

Co-administration with the following substances is formally prohibited as documented in regulatory labels:

  • Medicinal products that prolong the QTc interval: This includes certain anti-arrhythmics, antipsychotics, antidepressants, and antibiotics. The prohibition is based on the increased risk of serious ventricular arrhythmias.
  • Potent CYP3A4 Inhibitors: These substances, which include specific systemic azole antifungals and HIV protease inhibitors, cause a significant increase in Domperidone plasma concentrations by inhibiting its clearance, thereby elevating the cardiac risk.

Other Documented Interactions

  • Timing Separation Requirement: Antacids and antisecretory agents are documented to reduce Domperidone's oral absorption. Therefore, these agents should not be taken simultaneously with oral Domperidone, establishing a requirement for timing separation of administration.
  • Pharmacodynamic Antagonism: Anticholinergic drugs may counteract the medicine's prokinetic effects on the gastrointestinal tract.
  • Food Interaction: Regulatory labels specify administration before meals to optimize absorption, as taking it after meals delays and decreases the overall exposure.
  • Population-Specific Constraint: Due to the risk of increased plasma levels and associated cardiac risk, Domerid is formally contraindicated in patients with moderate or severe hepatic impairment.

Mechanism of Action

Domerid functions as a peripherally selective dopamine D2 and D3 receptor antagonist, blocking the actions of endogenous dopamine in specific systems outside of major central nervous system structures. This antagonism yields modulation across three key physiological domains.

Emetic Pathway Inhibition

This mechanism involves targeted signal inhibition in the Chemoreceptor Trigger Zone (CTZ), which lies outside the blood-brain barrier. Domerid blocks D2/D3 receptors, thereby inhibiting the activation of the central emetic signaling cascade. This limits the propagation of emetic signals, resulting in the physiological outcome of dampened emetic pathway activation.

Gastrointestinal Motility Enhancement

This is a cholinergic pathway modulation within the enteric nervous system of the gut wall. Domerid antagonizes D2 receptors on cholinergic nerve endings, removing dopamine's normal inhibitory control over acetylcholine release. The resultant increase in acetylcholine promotes smooth muscle contraction, modifying molecular steps that result in enhanced gastro-duodenal transit rate and elevated lower esophageal sphincter (LES) basal pressure.

Pituitary Endocrine Consequence

By blocking D2 receptors on the anterior pituitary gland, Domerid removes dopamine's tonic inhibitory control over prolactin secretion. This cascade results in the physiological consequence of elevated prolactin levels (hyperprolactinemia).

Dosage and Administration Information

How Domerid is Used: Administration Guidelines

Administration of Domerid (Domperidone) is governed by label-based instructions concerning route, dosage limits, timing, and duration. The medicine is primarily administered via the oral route (tablet or suspension), with a rectal route (suppository) also authorized for use in specific situations.


Standard Dosing and Frequency

Administration is generally restricted to the shortest duration necessary, which should not normally exceed seven consecutive days. The standard oral single dose is 10 mg, taken up to three times per day (TID), with a required minimum interval of eight hours between doses. The absolute maximum oral dose is 30 mg per day. For rectal administration, the standard single dose is 30 mg, given up to two times daily.


Timing and Procedural Conditions

For optimal absorption, Domerid must be taken 15 to 30 minutes before meals (pre-prandial). Tablets must be swallowed whole with water and should not be crushed. The oral suspension requires the use of a calibrated measuring device to ensure accurate volume is administered. If a dose is missed, it must be skipped entirely, and the patient should resume the next scheduled dose; the dose must not be doubled.


Population Adjustments and Constraints

Oral dosing is subject to weight and age restrictions, being limited to adolescents who are 12 years of age or older and weigh at least 35 kg. For patients diagnosed with severe renal impairment, standard guidelines recommend a reduction in dosing frequency (e.g., once or twice daily) due to the drug's slower clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Monotherapy

Research has focused on the compound's activity, which was studied in relation to specific inflammatory pathways. Initial Phase II studies in 200 adults with Rheumatoid Arthritis (RA) investigated whether use of the compound was associated with improvement in joint function and reduction in pain. The primary endpoint for these trials was the change in the DAS28 score (Disease Activity Score 28).

  • Key Findings:
    • One study reported a 30% greater decrease in the DAS28 score at 12 weeks in the treatment group compared to the placebo group.
    • A separate 6-month trial in individuals presenting with moderate to severe symptoms as defined by the study criteria examined the relationship between compound use and physical function (measured by HAQ-DI). Findings indicated that the treatment group experienced a positive change in the score, though differences from the control group were not statistically clear in all subsets of the population.

Studies evaluated the safety profile over the long term in adults in a two-year extension study. The most frequently reported adverse events included mild injection site reactions and upper respiratory tract infections.

The studied protocol involved taking the drug via subcutaneous injection once every two weeks.

Research on Combination Therapy

Research has explored the use of the compound in combination with a traditional DMARD (Disease-Modifying Anti-Rheumatic Drug). This research examined whether the combination was associated with pain reduction and improved radiological outcomes compared to the DMARD alone.

  • Analysis of Outcomes:
    • Studies investigated whether the compound was associated with a reduction in measures of disease progression, specifically joint damage visible on X-ray, when used alongside a traditional DMARD.
    • Research evaluated whether the combination demonstrated a different relationship with mobility outcomes compared to either compound as a monotherapy. Data from one 24-week study suggested a faster onset of effects in the combination group, but the long-term difference was not maintained throughout the study period.

Summary of Anti-inflammatory Markers

The drug’s activity was studied in relation to anti-inflammatory markers. Research examined the drug’s use specifically for Rheumatoid Arthritis. The current body of research focuses primarily on the outcomes detailed above.

Key Studies & References

  1. Guideline: Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value - Institute for Clinical and Economic Review (ICER)

Frequently Asked Questions (FAQ)

Common questions about Domerid (FAQ)


Q: How quickly does Domerid typically start to work?

A: Official product information indicates that the drug is absorbed quickly after oral administration. Peak concentrations in the bloodstream typically occur about one hour after a dose is taken, which reflects when the highest concentration of the active substance is in the bloodstream.


Q: How long do the effects of Domerid usually last?

A: The plasma half-life, which describes the time it takes for the body to eliminate half of the substance, is reported to be between 7 and 9 hours in healthy adults. This figure provides an indication of the time required for the body to eliminate the active substance.


Q: Is it normal to feel a bit drowsy after taking Domerid?

A: Some individuals may experience drowsiness (somnolence). When this effect occurs, it is documented in official regulatory documents as an uncommon reaction to the drug.


Q: What if Domerid doesn't seem to be working after a few days?

A: The medicine is generally prescribed for short-term use, typically not exceeding seven consecutive days, for the management of symptoms. Official guidance on its short-term use suggests that continued management should be discussed if symptoms persist.


Q: Is Domerid the same as [Name of similar drug]?

A: Domerid contains the active ingredient Domperidone, which is classified as a dopamine antagonist and a prokinetic agent. While other drugs may belong to the same therapeutic class, they are distinct chemical entities defined by their different active substances.


Q: Can Domerid be taken for general stomach discomfort?

A: The approved indications for Domerid primarily focus on relieving the symptoms of nausea and vomiting, especially when these are linked to delayed stomach emptying. Some regulatory sources also include the relief of other indigestion symptoms, such as bloating and feelings of fullness.


Q: Does Domerid cause weight gain or loss?

A: Changes in body weight, such as weight gain or weight loss, are not listed among the common, uncommon, rare, or very rare adverse events documented in the official regulatory product information.


Q: What should I do if I miss a dose of Domerid?

A: Official administration instructions are clear regarding missed doses. The official instruction is to skip the missed dose entirely and resume the treatment at the next scheduled time. It is specifically directed that a dose should not be doubled to compensate for the missed one.


Q: Are there any specific foods or drinks to avoid while taking Domerid?

A: Regulatory documents emphasize that Domerid should be taken before meals to help the body absorb the medicine optimally. The official label does not contain specific prohibitions for individual foods or drinks beyond general administration timing relative to meals.


Q: Does Domerid interact with herbal supplements?

A: Authoritative patient information based on regulatory standards often notes that the safety of combining Domerid with herbal or complementary remedies is not fully established. This is because these products are not typically subject to the same rigorous testing for potential drug interactions as prescription medicines.


Q: Can Domerid affect my ability to drive or operate machinery?

A: Since Domerid is associated with the uncommon side effect of drowsiness (somnolence), official patient information notes this potential effect. This is because drowsiness could affect a person’s ability to drive safely or operate complex machinery.


Q: Does Domerid help with nausea from motion sickness?

A: The drug is officially indicated for the relief of general symptoms of nausea and vomiting. The regulatory label provides a general indication but does not specifically list motion sickness as an approved use for the medicine.


Q: Is there a generic version of Domerid available?

A: Domerid is the brand name for the active ingredient Domperidone. Since Domperidone is recognized globally by an International Nonproprietary Name (INN), generic versions of the drug containing the same active substance are widely available in many markets, depending on local regulatory approval.


Q: What is the typical length of time a person uses Domerid?

A: Regulatory guidance restricts the use of Domerid to the shortest possible duration needed to manage symptoms, which is generally not permitted to exceed seven consecutive days for short-term symptomatic relief.


Q: Is Domerid habit-forming or addictive?

A: Domerid is not classified as a controlled substance in major regulatory jurisdictions, and official safety documents do not list habit-forming or addiction potential as a known risk associated with the drug's use.


Q: Does Domerid affect blood sugar levels?

A: Changes in blood sugar levels are not listed among the commonly reported side effects in the official regulatory documents. While the drug is sometimes used in research involving patients with conditions that affect blood sugar, this effect is not noted as a direct adverse reaction.


Q: Is Domerid a type of antihistamine?

A: No. Domerid is officially categorized as a dopamine antagonist and a prokinetic agent, which means it works by blocking dopamine receptors and promoting movement in the digestive tract. It does not belong to the pharmacological class of antihistamines.


Q: Why does Domerid need to be used with caution in people with pre-existing heart conditions?

A: Regulatory documents indicate that the drug is associated with a small, elevated risk of serious cardiac adverse reactions. This includes the potential for QTc prolongation (a change in the heart's electrical activity) and ventricular arrhythmia, a risk that is amplified in patients who already have heart conditions.


Q: Can Domerid be crushed, split, or chewed?

A: Official administration instructions for the tablet form of Domerid require that the medicine be swallowed whole with water. Official guidance states that the tablet formulation should not be crushed, split, or chewed to ensure the drug is administered as intended.


Q: Is Domerid used to treat stomach ulcers?

A: The official use of the drug is specifically indicated for the relief of symptoms related to nausea and vomiting. Regulatory documents do not list the treatment of stomach ulcers as an approved or recommended therapeutic use.


Q: Can Domerid be used to help with bloating?

A: Domerid's main role is to enhance the movement of the digestive tract, which helps to manage symptoms like nausea and vomiting. Since bloating and excessive fullness can be linked to slow digestive movement, some regulatory-approved uses may include the relief of these types of indigestion symptoms.


Q: Does Domerid have any known long-term cognitive side effects?

A: Official safety data lists extrapyramidal disorders, which are movement-related side effects, as very rare. However, long-term cognitive side effects, such as memory loss or cognitive decline, are not listed among the documented adverse reactions in regulatory product information.


Q: Why is it important to check for drug interactions before starting Domerid?

A: Official guidelines emphasize checking for interactions because co-administering Domerid with certain medicines—such as potent CYP3A4 inhibitors or QTc-prolonging drugs—can significantly slow down the clearance of Domerid. This increase in the drug's concentration in the body heightens the risk of serious cardiac events.

How should Domerid be stored and disposed of?

How to Store and Dispose of Domerid (Domperidone)

Official Storage Conditions

Domerid must be stored under controlled conditions to preserve its stability. The medicine requires storage at room temperature, typically defined as below 30 C. It is mandatory to keep the product away from heat, and it must not be frozen.

To prevent degradation, the product must be protected from light and moisture and stored in its original, tightly closed container. As with all medicines, Domerid must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Domerid must be disposed of properly according to regulatory guidelines. It should not be discarded in household trash or emptied into wastewater. The product should be disposed of via an approved drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Domerid found in:

A-Z Index: